Stocks and Investing Stocks and Investing
Thu, May 18, 2023
Wed, May 17, 2023

Serge Belanger Reiterated (ARQT) at Strong Buy and Held Target at $24 on, May 17th, 2023


Published on 2024-10-28 03:50:49 - WOPRAI, Serge Belanger
  Print publication without navigation


Serge Belanger of Needham, Reiterated "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy and Held Target at $24 on, May 17th, 2023.

Serge has made no other calls on ARQT in the last 4 months.



There are 5 other peers that have a rating on ARQT. Out of the 5 peers that are also analyzing ARQT, 0 agree with Serge's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Serge


  • Jonathan Block of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $33 on, Thursday, May 11th, 2023
  • Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $45 on, Wednesday, May 10th, 2023
  • Uy Ear of "Mizuho" Maintained at Strong Buy with Decreased Target to $57 on, Wednesday, May 10th, 2023
  • Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023

Contributing Sources